论文部分内容阅读
目的探究染色体重塑分子SNF5血清差异性表达用于早期诊断乳腺癌的可行性。方法选择2010年8月—2015年8月间于宁波大学医学院附属鄞州人民医院病理检查证实的196例乳腺癌患者(0期23例、Ⅰ期46例、Ⅱ期29例、Ⅲ期67例、Ⅳ期31例,平均年龄36.3岁)为研究对象,并选择同期在该院健康体检的64名志愿者(平均年龄37.9岁)为对照组。采用实时定量PCR检测2组外周血血清中SNF5的表达水平。采用统计学软件对2组SNF5水平进行统计学分析,并采用ROC曲线分析SNF5诊断乳腺癌的价值,进而探究染色体重塑分子SNF5血清差异性表达用于早期诊断乳腺癌的可行性。结果乳腺癌患者外周血血清中SNF5水平显著性高于对照组(P<0.05),0、Ⅰ、Ⅱ、Ⅲ、Ⅳ期乳腺癌患者SNF5水平分别是对照组的13、15、15、16、23倍(均P<0.05)。ROC曲线结果显示,SNF5诊断乳腺癌的敏感度与特异度分别为82%和93%,曲线下面积为0.8734(95%CI:0.923~0.944)。结论染色体重塑分子SNF5在乳腺癌患者中的表达明显升高,其可作为早期诊断乳腺癌肿瘤的生物标志物,具有敏感度、特异度高的优点。
Objective To investigate the feasibility of differentially expressed SNF5 serum for the early diagnosis of breast cancer. Methods A total of 196 cases of breast cancer confirmed by pathological examination from Yinzhou People’s Hospital Affiliated to Ningbo University Medical College between August 2010 and August 2015 (23 cases in stage 0, 46 cases in stage Ⅰ, 29 cases in stage Ⅱ, 67 cases in stage Ⅲ , 31 cases in stage Ⅳ, with an average age of 36.3 years) were selected as research objects. Sixty-four volunteers (mean age 37.9 years) in the same period were selected as the control group. Real-time quantitative PCR was used to detect the expression of SNF5 in peripheral blood of two groups. The statistical software was used to analyze the level of SNF5 in two groups and to analyze the value of SNF5 in the diagnosis of breast cancer by using ROC curve to explore the feasibility of differential expression of SNF5 serum in early diagnosis of breast cancer. Results The serum level of SNF5 in breast cancer patients was significantly higher than that in the control group (P <0.05). The SNF5 levels in 0, Ⅰ, Ⅱ, Ⅲ and Ⅳ breast cancer patients were respectively 13,15,15,16, 23 times (all P <0.05). The ROC curve showed that the sensitivity and specificity of SNF5 in diagnosing breast cancer were 82% and 93%, respectively. The area under the curve was 0.8734 (95% CI: 0.923-0.944). Conclusion The expression of chromosomal remodeling molecule SNF5 in breast cancer patients was significantly increased, which may be used as a biomarker for early diagnosis of breast cancer. It has the advantages of high sensitivity and specificity.